Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-299,137
Closed -$8.4M 2052
2026
Q1
$8.4M Buy
299,137
+177,627
+146% +$4.73M 0.16% 148
2025
Q4
$3.03M Buy
121,510
+3,010
+3% +$75.9K 0.07% 423
2025
Q3
$3.02M Buy
+118,500
New +$2.92M 0.07% 400
2024
Q4
Sell
-36,233
Closed -$1.05M 1546
2024
Q3
$1.05M Sell
36,233
-84,706
-70% -$2.47M 0.06% 433
2024
Q2
$3.38M Buy
120,939
+101,654
+527% +$2.8M 0.19% 118
2024
Q1
$535K Buy
+19,285
New +$535K 0.04% 679
2023
Q3
Sell
-8,067
Closed -$296K 1461
2023
Q2
$296K Sell
8,067
-35,466
-81% -$1.38M 0.03% 773
2023
Q1
$1.78M Sell
43,533
-14,309
-25% -$618K 0.21% 119
2022
Q4
$2.96M Buy
57,842
+16,519
+40% +$792K 0.44% 15
2022
Q3
$1.81M Buy
+41,323
New +$2.01M 0.18% 162
2021
Q4
Sell
-82,065
Closed -$3.53M 809
2021
Q3
$3.53M Buy
82,065
+62,522
+320% +$2.77M 0.64% 16
2021
Q2
$765K Buy
19,543
+11,619
+147% +$452K 0.19% 152
2021
Q1
$286K Sell
7,924
-28,461
-78% -$1.01M 0.08% 420
2020
Q4
$1.34M Buy
+36,385
New +$1.33M 0.56% 21

Other funds holding PFE

Y-Intercept (HK)'s PFE Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Pfizer (PFE) in Q2 2026, closing a stake of 299,137 shares — an estimated $8.4M sold.

Y-Intercept (HK) first reported a position in PFE in Q4 2020 and held it in 14 quarters. The position peaked at $8.4M in Q1 2026. 705 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 299,137 Pfizer shares in Q2 2026, an estimated $8.4M.
  • Y-Intercept (HK) first reported a position in Pfizer in Q4 2020 and held it in 14 quarters.
  • Y-Intercept (HK)'s Pfizer position peaked at $8.4M in Q1 2026.
  • 705 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.